Background: Recent meta-analyses of the efficacy of second-generation antidepressants for youth have concluded that such drugs possess a statistically significant advantage over placebo in terms of clinician-rated depressive symptoms. However, no meta-analysis has included measures of quality of life, global mental health, self-esteem, or autonomy. Further, prior meta-analyses have not included self-reports of depressive symptoms. Methods: Studies were selected through searching Medline, PsycINFO, and the Cochrane Central Register for Controlled Trials databases as well as GlaxoSmithKline's online trial registry. We included self-reports of depressive symptoms and pooled measures of quality of life, global mental health, self-esteem, and autonomous functioning as a proxy for overall well-being. Results: We found a nonsignificant difference between second-generation antidepressants and placebo in terms of self-reported depressive symptoms (k = 6 trials, g = 0.06, p = 0.36). Further, pooled across measures of quality of life, global mental health, self-esteem, and autonomy, antidepressants yielded no significant advantage over placebo (k = 3 trials, g = 0.11, p = 0.13). Discussion: Though limited by a small number of trials, our analyses suggest that antidepressants offer little to no benefit in improving overall well-being among depressed children and adolescents.

Keywords:
Antidepressant, Meta-analysis, Children, Adolescents, Depression, Quality of life, Self- and clinician ratings, Well-being
1.
Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL: Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328:879-883.
2.
Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-1345.
3.
Julious SA: Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients. Stat Methods Med Res 2013;22:190-218.
4.
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297:1683-1696.
5.
Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ: Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008;193:10-17.
6.
Poznanski E, Mokros H: Children's Depression Rating Scale - Revised (CDRS-R). Los Angeles, WPS, 1995.
7.
Bech P: Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 2005;19:313-324.
8.
Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M: Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004;26:13-17.
9.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC: Adjunctive atypical antipsychotics for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10:e1001403.
10.
Healy D: The assessment of outcomes in depression: measures of social functioning. Rev Contemp Pharmacother 2000;11:295-301.
11.
McKnight PE, Kashdan TB: The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 2009;29:243-259.
12.
Bech P, Tanghøj P, Cialdella P, Andersen HF, Pedersen AG: Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004;7:283-290.
13.
Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia C: Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011;31:569-576.
14.
Hewett K, Gee MD, Krishen A, Wunderlich H, Le Clus A, Evoniuk G, Modell JG: Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010;24:1209-1216.
15.
Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J: Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2009;23:531-538.
16.
Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A: Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-144.
17.
Uher R, Perlis RH, Placentino A, Dernovsek MZ, Henigsberg N, Mors O, Maier W, McGuffin P, Farmer A: Self-report and clinician-rated measures of depression severity: can one replace the other? Depress Anxiety 2012;29:1043-1049.
18.
Kaufman J, Birmaher B, Brent D, Rao U, Ryan N: Diagnostic Interview: Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). Pittsburgh, University of Pittsburgh School of Medicine, 1996.
19.
Hamilton M: A rating scale for depression. J Neurol Neurosurg 1960;23:56-61.
20.
Montgomery S, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
21.
von Knorring A, Olsson GI, Thomsen PH, Lemming OM, Hulten A: A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006;26:311-315.
22.
Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C: An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006;16:59-75.
23.
Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-772.
24.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
25.
Kovacs M: The Children's Depression Inventory (CDI). Psychopharmacol Bull 1985;21:995-998.
26.
Brooks SJ, Krulewicz SP, Kutcher S: The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial. J Child Adolesc Psychopharmacol 2003;13:337-349.
27.
Costello EJ, Angold A: Scales to assess child and adolescent depression: checklists, screens, and nets. J Am Acad Child Adolesc Psychiatry 1988;27:726-737.
28.
Reynolds WM: Reynolds Adolescent Depression Scale: Professional Manual. Odessa, Psychological Assessment Resources, 1987.
29.
Weinberg WA, Emslie GJ: Weinberg screening affective scales (WSAS and WSAS-SF). J Child Neurol 1988;3:294-296.
30.
Sigafoos AD, Feinstein CB, Damond M, Reiss D: The measurement of behavioral autonomy in adolescence: the autonomous functioning checklist. Adolesc Psychiatry 1988;15:432-462.
31.
Harter S: Manual for the Self-Perception Profile for Adolescents. Denver, University of Denver, 1988.
32.
Gowers SG, Harrington RC, Whitton A, Lelliott P, Beevor A, Wing J, Jezzard R: Brief scale for measuring the outcomes of emotional and behavioural disorders in children: Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). Br J Psychiatry 1999;174:413-416.
33.
Donnelly CL, Wagner KD, Rynn M, Ambrosini P, Landau P, Yang R, Wohlberg CJ: Sertraline in children and adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry 2006;45:1162-1170.
34.
SmithKlineBeecham: A Multi-Center, Double-Blind, Placebo Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression-Acute Phase. Final Clinical Report. SmithKlineBeecham, 1998.
35.
Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup J, Pathak S, Robins M, March J: Functioning and quality of life in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45:1419-1426.
36.
Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. San Diego, Academic Press, 1985.
37.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
38.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
39.
Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003;290:1033-1041.
40.
Diener E, Suh EM, Lucas RE, Smith HL: Subjective well-being: three decades of progress. Psychol Bull 1999;125:276-302.
41.
Mayes TL, Bernstein IH, Haley CL, Kennard BD, Emslie GJ: Psychometric properties of the children's depression rating scale-revised in adolescents. J Child Adolesc Psychopharmacol 2010;20:513-516.
42.
Ambrosini PJ, Metz C, Bianchi MD, Rabinovich H, Undie A: Concurrent validity and psychometric properties of the Beck Depression Inventory in outpatient adolescents. J Am Acad Child Adolesc Psychiatry 1991;30:51-57.
43.
Kashani JH, Sherman DD, Parker DR, Reid JC: Utility of the Beck Depression Inventory with clinic-referred adolescents. J Am Acad Child Adolesc Psychiatry 1990;29:278-282.
44.
Olino TM, Yu L, Klein DN, Rohde P, Seeley JR, Pilkonis PA, Lewinsohn PM: Measuring depression using item response theory: an examination of three measures of depressive symptomatology. Int J Methods Psychiatr Res 2012;21:76-85.
45.
Brooks SJ, Kutcher S: Diagnosis and measurement of adolescent depression: a review of commonly utilized instruments. J Child Adolesc Psychopharmacol 2001;11:341-376.
46.
Reynolds WM, Mazza JJ: Reliability and validity of the Reynolds Adolescent Depression Scale with young adolescents. J School Psychol 1998;36:295-312.
47.
Walker L, Merry S, Watson PD, Robinson E, Crengle S, Schaaf D: The Reynolds Adolescent Depression Scale in New Zealand adolescents. Aust NZ J Psychiatry 2005;39:136-140.
48.
Merry SN, Stasiak K, Shepherd M, Frampton C, Fleming T, Lucassen MF: The effectiveness of SPARX, a computerised self help intervention for adolescents seeking help for depression: randomised controlled non-inferiority trial. BMJ 2012;344:e2598.
49.
Pirkis JE, Burgess PM, Kirk PK, Dodson S, Coombs TJ, Williamson MK: A review of the psychometric properties of the Health of the Nation Outcome Scales (HoNOS) family of measures. Health Qual Life Outcomes 2005;3:76.
50.
Achenbach TM, McConaughy SH, Howell CT: Child/adolescent behavioral and emotional problems: implications of cross-informant correlations for situational specificity. Psychol Bull 1987;101:213-232.
51.
Endicott J, Nee J, Yang R, Wohlberg C: Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): reliability and validity. J Am Acad Child Adolesc Psychiatry 2006;45:401-407.
52.
Sechter D, Troy S, Paternetti S, Boyer P: A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999;14:41-48.
53.
Muris P, Meesters C, Fijen P: The Self-Perception Profile for children: further evidence for its factor structure, reliability, and validity. Pers Individ Dif 2003;35:1791-1802.
54.
Blom EH, Bech P, Hogberg G, Larsson JO, Serlachius E: Screening for depressed mood in an adolescent psychiatric context by brief self-assessment scales - testing psychometric validity of WHO-5 and BDI-6 indices by latent trait analyses. Health Qual Life Outcomes 2012;10:149.
55.
Tomba E, Bech P: Clinimetrics and clinical psychometrics: macro- and micro-analysis. Psychother Psychosom 2012;81:333-343.
56.
Cheung AH, Emslie GJ, Mayes TL: Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005;46:735-754.
57.
Emslie GJ, Rush J, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-1037.
58.
Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobsen JG: Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-1214.
59.
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004;292:807-820.
60.
Boylan K, Romero S, Birmaher B: Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology (Berl) 2007;191:27-38.
61.
Gentile S: Antidepressant use in children and adolescents diagnosed with major depressive disorder: what can we learn from published data? Rev Recent Clin Trials 2010;5:63-75.
62.
Leckman JF: The risks and benefits of antidepressants to treat pediatric-onset depression and anxiety disorders: a developmental perspective. Psychother Psychosom 2013;82:129-131.
63.
Offidani E, Fava GA, Tomba E, Baldessarini RJ: Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 2013;82:132-141.
64.
Hammad TA: Relationship between psychotropic drugs and pediatric suicidality. 2004. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-0-tab08-hammads-review.pdf.
65.
Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ, Lipschitz A, Machin A, Wilkinson C: Paroxetine treatment in children and adolescents with major depressive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006;45:709-719.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.